Improvement of cardiac function after treatment with octreotide followed by trans-sphenoidal surgery in an acromegalic patient who presented with congestive heart failure.
Cardiovascular disease is a major cause of mortality and morbidity in patients with acromegaly. We describe the case of a 43-year-old man with acromegaly who presented with severe congestive heart failure. Treatment with the somatostatin analog octreotide improved cardiac function with an increase in left ventricular ejection fraction (LVEF) from 11% to 27%. LVEF further increased to 43% after trans-sphenoidal surgery. Recovery was uneventful. We emphasize the need for early diagnosis and effective treatment of acromegaly to prevent cardiovascular complications. Octreotide therapy or trans-sphenoidal surgery, if possible, should be considered to control cardiac function even in acromegalic patients with severe congestive heart failure.
Shimakura
Atsuhiro
A
Department of Internal Medicine, Kouseiren Takaoka Hospital, Toyama, Japan.
Miyakoshi
Hisatsugu
H
Ohkuwa
Hitoshi
H
Kitabayashi
Masahiro
M
Komai
Toshio
T
Hisada
Azusa
A
Aoki
Koichiro
K
Sakagami
Satoru
S
Kobayashi
Ken-ichi
K
Takata
Shigeo
S
D000172:Acromegaly / Q000188:drug therapy* / Q000503:physiopathology / Q000601:surgery*; D000328:Adult; D003131:Combined Modality Therapy; D013006:Growth Hormone / Q000097:blood; D006333:Heart Failure / Q000150:complications*; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008297:Male; D015282:Octreotide / Q000627:therapeutic use*; D016277:Ventricular Function, Left / Q000187:drug effects
D006728:Hormones; D007334:Insulin-Like Growth Factor I; D013006:Growth Hormone; D015282:Octreotide